Tuesday, August 27, 2019

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Conditions


Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)today announced its receipt of a new patent granted in Australia: #2016367037 / Grant Date August 15, 2019 – “Stable ready-to-drink beverage compositions comprising lipophilic active agents.” According to the update, this increases Lexaria’s portfolio to 16 awarded patents protecting its DehydraTECH(TM) drug delivery platform, with eight in the USA and eight in Australia. The new Australian patent, together with Australian Patent #2016367036 announced on August 15, 2019, are the first granted in Lexaria’s second and third patent families that differ from the company’s original patent family, “Food and beverage compositions infused with lipophilic active agents and methods of use thereof.” These new patents include claims for DehydraTECH technology with respect to food and beverage use and also, for the first time, for pharmaceutical applications for delivery of cannabinoids as methods of treating certain conditions. These include, but are not limited to heart disease, neurological diseases, obesity, metabolic and appetite disorders, hepatic diseases, diabetes, cancer via chemotherapy, irritable bowel syndrome (“IBS”), marijuana abuse, and opioid, alcohol, nicotine or cocaine addiction.

To view the full press releases, visit http://ibn.fm/JemJa

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php


No comments: